Researchers from the US have shown that combination therapy with sitagliptin and metformin results in a substantial and additive glycemic improvement in patients with type 2 diabetes. Sitagliptin ...

Zydus Lifesciences announces CVS Caremark agreement and FDA priority review for diabetes and Menkes disease treatments.

Recently, the US FDA approved initial combination therapy with sitagliptin and metformin (Janumet™) in order to help more patients with Type 2 diabetes mellitus get closer to accepted glycemic ...

Zydus enters agreement with CVS Caremark to add Zituvio, Zituvimet and Zituvimet XR to its template formulary: Our Bureau, Mumbai Tuesday, January 7, 2025, 17:15 Hrs [IST] Zydus L ...

Zydus Pharmaceuticals USA Inc President & CEO Punit Patel said the relationship is a strong validation of Zydus' strategic ...

With the two active components, sitagliptin and metformin, Janumet has a comprehensive mechanism of action that targets all three key defects of T2DM for improved glycemic control: diminished ...

Zydus Lifesciences has partnered with CVS Caremark to add its diabetes medications, Zituvio, Zituvimet, and Zituvimet XR, to ...

Ahmedabad: Zydus Lifesciences Ltd, a global healthcare company announced that it has entered into an agreement with CVS ...

CVS Caremark will add Zydus' ZituvioTM and combination products to its template formulary starting January 1, 2025 ...

The stock price of Zydus Lifesciences surged over 5 per cent in the Tuesday trading session after the drugmaker’s wholly ...

Zydus Lifesciences reacted sharply to the development in Tuesday's trade with the counter rising 5.23 percent to an intraday high of Rs 1,011.75 per share on the NSE.

Sitagliptin, metformin (as HCl) ext-rel; 50mg/500mg, 50mg/1000mg, 100mg/1000mg; tabs. Individualize. Swallow whole. Take once daily with a meal, preferably in the evening. Not currently treated ...